Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by Bigboyoneon Dec 28, 2016 8:48am
227 Views
Post# 25646074

Capitol Cube Rates Aralez and its not all good-

Capitol Cube Rates Aralez and its not all good-Capitol Cube Says we so far, we lack good leadership and a forward real direction despite Adams past record, Profit margins at best, will be slim. Aralez can change that outlook  by having a real development plan and building some momentum on top of that, Etc-

Somthing has to be a-miss, as the Dow aproaches 20,000 and we are at $4.60 a share.

I do hope 2017 is a better year for all.


https://www.capitalcube.com/blog/index.php/aralez-pharmaceuticals-inc-value-analysis-nasdaqarlz-december-27-2016/
<< Previous
Bullboard Posts
Next >>